Please, Signup (Login) to subscribe or trade (demo)
Dynavax Technologies Corporation stock price
Dynavax Technologies Corporation latest news:
Third time's the charm: Dynavax shares rocket 18% on hepatitis B vaccine approval
Marking a positive end to the company's prolonged roller-coaster ride, including major layoffs earlier this year. Dynavax Technologies Corp. (DVAX) shares surged 18% in premarket trade Friday after the company said its hepatitis B vaccine was approved by the Food and Drug Administration. The vaccine, Hepislav-B, is the first new hepatitis B vaccine in the U.S. in decades and consists of just two doses over a month, compared with current hepatitis B vaccines' three doses over six months.
BRIEF-Dynavax says FDA approves Heplisav-B for Hepatitis B prevention in adults
Dynavax Technologies Corp(DVAX). * Dynavax(DVAX) announces FDA approval of Heplisav-B for prevention of Hepatitis B in adults. * Dynavax Technologies Corp (DVAX) - expects to commercially launch Heplisav-B in United States in Q1 of 2018 Source text for Eikon: Further company coverage: